ICMR study reveals Bharat Biotech's COVAXIN neutralises multiple variants of SARS-CoV-2
ICMR study reveals Bharat Biotech's COVAXIN neutralises multiple variants of SARS-CoV-2
Share:

The Indian Council of Medical Research (ICMR) said on Wednesday that Indigenously-developed Covid-19 vaccine Covaxin, made by Bharat Biotech, neutralises multiple variants of SARS-CoV-2 and effectively neutralises the double mutant strain.

The Research council also informed that the Indian vaccine effectively neutralises the double mutant strain as well, which is being reported in many parts of the country.

In its twitter handle, the ICMR officially  tweeted, "ICMR study shows #COVAXIN neutralises against multiple variants of SARS-CoV-2 and effectively neutralises the double mutant strain as well,"

This development comes amid the second wave of the COVID-19 pandemic being witnessed across the country. As per the union health ministry, India on Wednesday crossed a landmark with more than 13 crore people administered with doses of COVID-19 vaccines.

More than 29 Lakh vaccine doses were administered in the last 24 hours. "Cumulatively, 13,01,19,310 vaccine doses have been administered through 19,01,413 sessions, as per the provisional report till 7 am today," the health ministry said.

 

Global research: Brazilian COVID-19 variant much more transmissible than other strains

New Study reveals that multivitamins, omega-3, probiotics may cut risk of COVID-19

What AIIMS chief says: Remdesivir is not a magic bullet

 

Join NewsTrack Whatsapp group
Related News